Consensus Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE 04:00:00 2026-09-28 pm EDT			5-day change	1st Jan Change
2.500 ^USD	-0.79%		-15.82%	-9.09%

Sep. 20	Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index	CI
Sep. 18	William Blair Initiates Perspective Therapeutics With Outperform Rating	MT

Evolution of the Average Target: Perspective Therapeutics, Inc.

Evolution of the Target Price: Perspective Therapeutics, Inc.

Changes in Analyst Recommendations: Perspective Therapeutics, Inc.

2a4354ba98f5ea1234a0695d.93N_z1ymcNqXldvO3kqcfYBhupkDOPTeOXOPjSOSFDQ.jjQvqS70CbPtz-77nDDMEuY32_1uWqeyDSC9yWLWZn2wJTW-HcdJtNPHuA~0173067d71c8fa0fdaf56adefd67c254

Analysts' recommendations: Perspective Therapeutics, Inc.

Sep. 18	William Blair Initiates Perspective Therapeutics With Outperform Rating	MT
Aug. 19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
Aug. 14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
Aug. 11	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT
Mar. 18	UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating	MT
Mar. 18	B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating	MT
Mar. 17	RBC Cuts Price Target on Perspective Therapeutics to $14 From $18, Keeps Outperform, Speculative Risk	MT
Feb. 19	Piper Sandler Initiates Coverage on Perspective Therapeutics With Overweight Rating	MT
Nov. 18	B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating	MT
25-10-10	BTIG Research Initiates Coverage on Perspective Therapeutics With Buy Rating, $14 Price Target	MT
25-06-23	B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating	MT
25-06-03	RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk	MT
25-05-14	Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating	MT
25-05-13	Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating	MT
25-04-07	Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating	MT
25-03-27	RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk	MT
25-03-13	HC Wainwright Initiates Coverage on Perspective Therapeutics With Buy Rating, $10 Price Target	MT
25-03-10	Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target	MT
24-11-26	B. Riley Securities Adjusts Price Target on Perspective Therapeutics to $9 From $17, Keeps Buy Rating	MT
24-11-25	BofA Securities Downgrades Perspective Therapeutics to Neutral From Buy, Price Target is $6	MT
24-11-25	RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk	MT
24-11-13	RBC Trims Price Target on Perspective Therapeutics to $25 From $27, Keeps Outperform, Speculative Risk	MT
24-10-24	UBS Initiates Perspective Therapeutics at Buy With $20 Price Target	MT
24-10-11	Top Midday Decliners	MT
24-10-11	Wedbush Adjusts Price Target on Perspective Therapeutics to $20 From $25, Maintains Outperform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PERSPECTIVE THERAPEUTICS, INC.					+391.43%
	LONZA GROUP AG					+17.8%
	IQVIA HOLDINGS INC.					+3.17%
	REVOLUTION MEDICINES, INC.					+27.25%
	BEONE MEDICINES AG					+17.93%
	CELLTRION, INC.					+50.19%
	MEDPACE HOLDINGS, INC.					-5.54%
	TEMPUS AI, INC.					-19.42%
	EUROFINS SCIENTIFIC SE					-8.23%
	ASCENDIS PHARMA A/S					+34.94%
	Average					+50.95%
	Weighted average by Cap.					+16.77%